Emergent BioSolutions, MorphoSys Tie Up on Cancer Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 5:08PM CDT
Emergent BioSolutions has inked a deal on ES414.
Final Glance: Biotechnology companies
AP - Wed Aug 20, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
3 Reasons Gilead Science, Inc.’s Stock Could Rise
Brian Orelli, The Motley Fool - Motley Fool - Wed Aug 20, 4:36PM CDT
Gilead Sciences is trading near all-time highs, but there's still potential for the stock price to go even higher. Here are three things that could send shares higher if they come to fruition. Source: Gilead. 1. Sales of Gilead's...
Hospira Sues FDA on Generic Precedex Approval, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 4:00PM CDT
Hospira (HSP) has challenged the FDA's decision to clear generic Precedex.
Healthcare Enjoys Growth Trends: 3 Medical Stocks to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 3:27PM CDT
Favorable industry trends in the pharma and bio-tech space makes the healthcare sector a lucrative investment destination.
Oncothyreon (ONTY) Slumps, Tecemotide Fails Phase I/II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 2:53PM CDT
Shares of Oncothyreon Inc. (ONTY) slumped significantly after collaboration partner Germany-based Merck KGaA (MKGAY) informed the former that a phase I/II study, on tecemotide, did not meet its primary endpoint.
Midday Glance: Biotechnology companies
AP - Wed Aug 20, 12:50PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Wed Aug 20, 11:21AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 20, 10:08AM CDT
Last week, hepatitis C virus treatments remained in focus with Achillion and Gilead providing updates on ACH-3102 and Sovaldi, respectively.
Record Earnings & Stronger Growth in Q2 - Earnings Trends
Sheraz Mian - Zacks Investment Research - Wed Aug 20, 2:57AM CDT
Record Earnings & Stronger Growth in Q2 - Earnings Trends
Record Earnings & Stronger Growth in Q2 - Earnings Outlook
Sheraz Mian - Zacks Investment Research - Wed Aug 20, 2:57AM CDT
Record Earnings & Stronger Growth in Q2 - Earnings Outlook
Will Roche (RHHBY) Buy the Remaining Stake in Chugai? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 4:55PM CDT
As per a news report from Bloomberg, Switzerland-based oncology major, Roche (RHHBY) is set to buy the remaining 39.5% stake in its Japanese subsidiary, Chugai Pharmaceutical Co Ltd for approximately $10 billion.
Amgen (AMGN) Reports Encouraging Top-Line Data on AMG 416 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 4:25PM CDT
Amgen Inc. (AMGN) announced that AMG 416 has met the primary as well as secondary endpoints in the second phase III registration study.
Pfizer Submits Palbociclib Marketing Application to the FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 3:20PM CDT
Pfizer Inc. (PFE) announced that it has submitted the marketing application for its oncology candidate, palbociclib, to the FDA.
Biogen Strengthens MS Portfolio with Plegridy FDA Approval - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 19, 12:20PM CDT
Plegridy's less frequent dosing schedule could help it gain share from other beta interferon treatments.
Technical Updates, Drug Recommendations, and Upcoming Events - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Humana
PR Newswire - Tue Aug 19, 8:20AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Express Scripts Holding Company (NASDAQ: ESRX) and Humana Inc. (NYSE: HUM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5808-100free.
PDL BioPharma Misses on Q2 Earnings due to Higher Expenses - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 8:10AM CDT
PDL BioPharma (PDLI) posted second-quarter 2014 earnings of 52 cents per share, below the Zacks Consensus Estimate of 55 cents.
Celladon Corp. (CLDN) Jumps: Stock Adds 11.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 7:51AM CDT
Celladon Corporation (CLDN) was a big mover last session, as its shares rose over 11% on the day.
Achillion Pharmaceuticals Soars on Mid-Stage HCV Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 3:45PM CDT
Achillion Pharmaceuticals (ACHN) reported positive interim results from a phase II study on ACH-3102.